89bio, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Rohan Palekar
- Full Time Employees
- 93
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 142 Sansome Street San Francisco CA United States of America 94104
- IPO Date
- Nov 11, 2019
- CIK
- 0001785173
- Website
- 89bio.com
- Similar Companies
- Business
- 89bio, Inc. (Ticker: ETNB) is a biopharmaceutical company focused on the development and commercialization of novel therapies for the treatment of non-alcoholic steatohepatitis (NASH) and related metabolic diseases. The company’s main products and services include the development of drug candidates targeting liver fibrosis and metabolic dysfunction, with its lead product candidate being a novel biologic designed to modulate key metabolic and fibrotic pathways. 89bio offers clinical-stage therapeutic solutions and specializes in biologic drug development specifically for chronic liver diseases. Headquartered in San Francisco, California, 89bio operates primarily in the United States but also has clinical development activities extending internationally. Founded in 2018, the company positions itself within the biopharmaceutical industry focusing on hepatology and metabolic disease segments, targeting healthcare providers, research institutions, and pharmaceutical partners as its primary customers. Recent major company changes include scaling up clinical development programs and progressing with late-stage clinical trials of its lead product candidate. 89bio has also been active in expanding its strategic partnerships and research collaborations to enhance its drug pipeline and accelerate commercialization efforts. These operational developments reflect a significant strategic expansion to advance its portfolio in the liver disease therapeutic market. In summary, 89bio, Inc. develops biologic therapies for NASH and metabolic diseases, focusing on clinical-stage drug candidates targeting fibrosis and metabolism. It maintains a growing pipeline and strategic partnerships to support advancement and commercialization, operating from its San Francisco headquarters since 2018.
3 Investable Laggards In An Overbought Market
My Top 3 Pharma Stocks
89bio Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNB
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of 89bio, Inc. (NASDAQ: ETNB)
3 Potential Biotech Acquisition Targets
89BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNB
Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push
ETNB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of 89bio, Inc. Is Fair to Shareholders
Roche to buy US biotech 89bio in $3.5bn deal
Shareholder Alert: The Ademi Firm Investigates Whether 89bio, Inc. is Obtaining a Fair Price for its Public Shareholders
Roche to Buy 89bio for Up to $3.5 Billion
Roche to acquire liver drug developer 89bio for up to $3.5 billion
89bio, Inc. Announces Agreement to be Acquired by Roche
89bio, Inc. (ETNB) Presents At Cantor Global Healthcare Conference 2025 (Transcript)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio, Inc. (ETNB) Presents At Citi's Biopharma Back To School Conference Transcript
89bio: Promising As Pegozafermin Nears Phase 3 Readout
89bio (ETNB) Q2 R&D Jumps 131%
89bio Reports Second Quarter 2025 Financial Results and Corporate Updates
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)